RE:RE:Grail Galleri test vs Stagezero Aristotle test Now you are clueing in, the one calling everyone out is the one trying to play it, I have a PM from basementBOY that this was the first stock he ever bought, so ya he broke his piggy bank to buy 100 shares.
LithLover wrote: This is not a pump these are facts taken from published oncology reports from both companies. Maybe it's Jonny with the agenda and multiple accounts.
LithLover wrote: Grail early detection (Stage 1) results was 17% in one study and 39% in another with false positives of 30%
Aristotle (Stage 1) was 55.6% with false positive under 7%.
Both are priced the same at $949 USD.
-------------------------
- One study showed that Galleri detected 39% of stage I, 69% of stage II, 83% of stage III and 92% of stage IV cancers. While the test more accurately detected cancers of increasing stage, it failed to detect almost 60% of stage I cancers.
- In another study published by GRAIL to validate Galleri, the test detected 51.5% of cancers. Again, the sensitivity of the test increased with the stage of cancer. Galleri identified about 77% of stage III and 90% of stage IV cancers. Once again, however, the test failed to dependably detect early-stage cancers, finding only about 17% of stage I cancers and 40% of stage II cancers.
- Early results of yet another study have also been reported by GRAIL. The PATHFINDER study looked at people older than 50 who had an elevated risk for cancer because they were smokers, previously had cancer or had an inherited mutation that significantly increased their cancer risk. In this study, the frequency of false-positive results produced by Galleri was an issue; almost 30% of the positive tests were false positives (the tests were positive for cancer when the individuals had no cancer). False-positive results can lead to additional tests, anxiety and potentially surgical biopsies.
--------
Aristotle classified cancer profiles with sensitivities from 55.6-100
The mean false positive rate for the 11 cancer classes ranged from 0.3- 6.8%.